Miltenyi Biotec, Cesca Therapeutics' Subsidiary TotipotentRX Announce Multi-Year Commercial Agreement for Bone Marrow Transplantation
Cesca Therapeutics Inc. (NASDAQ: KOOL) today announced that its subsidiary, TotipotentRX, has signed a multi-year distribution agreement with Miltenyi Biotec GmbH (Germany) for clinical product sales throughout India. As part of the agreement, TotipotentRX's advanced haploidentical transplant program will incorporate Miltenyi Biotec's CliniMACS® Cell Separation System, used for selecting beneficial cells or depleting donor immune cells from grafts that may interfere with engraftment in preparation for bone marrow transplantation. TotipotentRX provides specialized clinical cell manufacturing technology, services and expertise to major hospital networks in the rapidly growing Indian transplant market, including its exclusive agreement with Fortis Healthcare. With this agreement Miltenyi reinforces Cesca's leadership position while strategically positioning itself for future growth in Asia.
Venkatesh Ponemone, Ph.D., Executive Director and Director of GMP Laboratory and Clinical Affairs at Cesca's subsidiary TotipotentRX, stated, "This landmark agreement is the beginning of what is anticipated to be a long and fruitful relationship with Miltenyi Biotec that will benefit Indian hematology and oncology patients. The combination of expertise, services and products that we now jointly provide is unmatched in the region. I believe this to be a crucial milestone in